RxDoctor Payments Data

Laura Peters, NP

Adult Health · Aurora, CONPI 1245574847

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Novo Nordisk at 37.5% of the total. 2025 is the largest year on record at $230, more than ten times the $16 reported in 2022.

$457in general payments, 2019–2025

Across 15 payments — averaging $30.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$171
  • Boston Scientific$56
  • AstraZeneca$55
  • Pfizer$42
  • Abbott$39
  • Lexicon Pharmaceuticals, Inc.$27
  • plus $66 from 3 others
$29,978in research payments, 2019–2025

Across 8 payments — averaging $3747.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$30K

What the payments were for

  • Food & beverage$457100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$457 in reported general payments places this provider in the 60th percentile of 430 adult health providers in Colorado.

See all adult health providers in Colorado

Medicare billing

Part B allowed, 2024
$23,946
Medicare patients
116
Services billed
216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sirolimus125$100,965
EliquisApixaban42$57,491
Everolimus40$50,714
JardianceEmpagliflozin41$50,489
Tacrolimus291$45,687
Repatha SureclickEvolocumab32$35,901
Mycophenolic AcidMycophenolate Sodium95$29,205
Mycophenolate Mofetil141$18,935
Cyclosporine ModifiedCyclosporine, Modified35$4,807
Valganciclovir Hcl21$3,921
Rosuvastatin Calcium168$3,687
GengrafCyclosporine, Modified13$3,302
Losartan Potassium316$2,903
Omega-3 Acid Ethyl Esters22$2,697
Ezetimibe85$2,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$42$57,49142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 430 adult health providers in Colorado.

Other adult health in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →